Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. - Wikidata - awgldk - TriplyDB

Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses.

Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses.

http://www.wikidata.org/entity/Q40735997

about

Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits.Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgeni Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpes Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge Developing an asymptomatic mucosal herpes vaccine: the present and the future.Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine Strategies for intranasal delivery of vaccines Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.Vaccine strategies against human cytomegalovirus infection.Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.New concepts in herpes simplex virus vaccine development: notes from the battlefield.Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation.Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocul Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products.Vaccination against rheumatic heart disease: a review of current research strategies and challenges.Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.Cyclopeptide scaffolds in carbohydrate-based synthetic vaccines.Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine.Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer.Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides.Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8+ TEM and TRM Cell Responses Against Herpes Infection and Disease‡.

P2860

Q21092179-3B4B4EC2-094A-486A-8981-65807D75F1E3 Q21296712-6B647BD8-48CF-4E02-B453-A905CB461D26 Q30847945-56F84380-F201-4DFE-B4D7-D83F64D2F422 Q33551402-FE08B8DC-8CA3-43AD-A385-0C3B39C452BA Q33614657-50CDA314-EEE0-4813-9C49-717BCA007908 Q33725145-DC22913B-B9C7-4ABF-BF12-0E79784903AB Q33887085-C77867E2-825A-4514-A89B-74FD6F3785A1 Q33956199-46D78C0F-A73B-4334-B0D0-03D85F27D665 Q33993731-5D3E6BE0-F554-4144-A4D9-84A9DD36771A Q34131142-B0E43D4A-0BEE-4A86-B8BB-E69AD0BFE7D3 Q34193431-FA3C3D8F-ED83-4F27-9425-855FBCB24D82 Q34228659-486A0109-4896-4059-9445-DD1A8FCC883A Q35122383-371468A4-C531-4A44-94BD-3A95B3675201 Q35487893-49C76E64-B751-49DA-9A85-51EDAD4B9EAB Q35802953-CC968117-E889-4A0C-974D-ECD85B22140F Q35871689-65EBC28C-18CE-42D4-ADC2-2B86E05FD54E Q35881975-F42766F4-D220-49B2-8BC3-F72E80535D9C Q36025675-314F0200-55AA-4DD8-8A3E-7CE2F2C3E603 Q36514771-FCE106A4-78C3-4030-BDF2-1498B0F883A6 Q36520832-42C9171F-538F-4F39-93D0-8BC8973EED3E Q36555158-2C0BFD37-1C7C-4850-9300-976EE7DF83B1 Q36839736-3CF0BB61-44B5-4F9D-BC1C-BAB8D4F18DDA Q36898071-804B63B7-0625-42FC-A7C9-F4428F3579F6 Q37118262-57E83B2B-FD01-4823-97DB-8FE3E8E66D01 Q37384857-D6EF692D-2DA7-406F-BE94-35064EB9F54C Q37559627-D8D4DC65-BFFB-42E0-BC72-EBEAB827EB01 Q37560770-474BCA27-BCE3-4A98-A0A4-FD3F93128DA0 Q37661001-37FFC478-7B9B-4466-A7AD-484ACB6D39DC Q38021366-F7B180FF-C689-4A61-A2D8-330AF3893F1F Q38153040-46AAE50F-290F-43F5-97F2-7A58C048026E Q39169715-DF4E4178-1E96-4436-86B7-3D5E28733708 Q39172114-82D36AC0-DEF3-480F-A5A6-B428B50F4ADF Q40054175-3942CFDA-0C9A-4B82-A27C-96BE0599BF74 Q40144775-997DF4EF-2D00-4613-A396-EDF4CA5ABC66 Q41195668-7499805D-2FF6-42CB-BB5C-35901DA0CCEA Q50043299-6F97664C-E4DA-4BE5-BEB2-AFEA2248D96B

P2860

Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses.

http://www.wikidata.org/entity/Q40735997

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Intranasal administration of a ...... ces systemic immune responses.

@en

type

label

Intranasal administration of a ...... ces systemic immune responses.

@en

prefLabel

Intranasal administration of a ...... ces systemic immune responses.

@en

P1433

Q40735997-D3BB5C40-BFE3-4F24-9DC9-C3AB9F6289D8

P1476

Q40735997-9E1041CB-5F34-4615-B258-6C6090DA8089

P2093

Q40735997-0184FC86-E417-46AB-99E6-F005FFF051B1

Q40735997-48BC765D-BE31-47F1-97E3-0FB9D0BAC72D

Q40735997-4D330CBB-5844-4BA3-8CD1-831D29AC6611

Q40735997-897C7024-EBF4-4360-A31D-FAADB5283492

Q40735997-8DCAFE68-34E4-4CE4-98D7-1B91F5634BD9

P2860

Q40735997-0053B555-1DB2-4910-B182-D6A8C1D2855E

Q40735997-024B216D-0A6B-4CBD-A036-2499BDC3E1AE

Q40735997-06D8AF02-E3F7-4889-8F2F-954278C22859

Q40735997-1423A72B-A119-438D-A64B-ACCE8551F734

Q40735997-1B85B798-0628-4B80-8466-E46D307C513C

Q40735997-276B139C-6834-44E3-9038-15E53B49E562

Q40735997-29556541-DCC9-45C0-A098-CB65863774AF

Q40735997-2DE44018-0F6B-4A2C-BA6F-34B16C0E20F1

Q40735997-2FB80268-330B-43C2-957B-E51332635544

Q40735997-306F8EE2-04A7-4BF9-B9F8-A04054D4251F

P304

Q40735997-F8F3E01B-A569-492C-8D41-26D4B2B3A8E0

P31

Q40735997-EC1F1822-AA58-4EA4-9153-7AB7028124CE

P356

Q40735997-AAEBFA0F-2560-4734-858B-32FA3CE02A54

P433

Q40735997-F9FA39FF-8419-43DA-BCE2-6588CBA5CA76

P478

Q40735997-B918F08E-9356-4DDC-9F6C-8B84586894E3

P577

Q40735997-A25FA7A6-B767-471A-940C-CCE8545D91BB

P5875

Q40735997-0912597C-84BA-46A7-8A93-2452BEF37C0F

P698

Q40735997-2AA21D0F-3C71-4446-9119-DAF429230721

P932

Q40735997-E2C031B1-8188-44A1-96A7-80B1C08E6AB8

P356

J.1365-2567.2002.01396.X

P1433

P1476

Intranasal administration of a ...... ces systemic immune responses.

@en

P2093

Catherine Auge

http://www.w3.org/2001/XMLSchema#string

Don J Diamond

http://www.w3.org/2001/XMLSchema#string

James F Primus

http://www.w3.org/2001/XMLSchema#string

Lbachir BenMohamed

http://www.w3.org/2001/XMLSchema#string

Radhika Krishnan

http://www.w3.org/2001/XMLSchema#string

P2860

Immunostimulation by bacterial components: I. Activation Of macrophages and enhancement of genetic immunization by the lipopeptide P3CSK4.

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides.

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

Synthetic lipopeptides as novel adjuvants.

A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity.

Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans.

Protection against measles virus-induced encephalitis by antibodies from mice immunized intranasally with a synthetic peptide immunogen.

The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide.

Comparison of the role of complement in immunity to Schistosoma mansoni in rats and mice.

P304

113-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2567.2002.01396.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11395236

http://www.w3.org/2001/XMLSchema#string

P698

11972639

http://www.w3.org/2001/XMLSchema#string

P932

1782698

http://www.w3.org/2001/XMLSchema#string